Kurin, Inc. Reports Record Q3 Sales

Kurin, Inc., the inventor and manufacturer of Kurin<sup”>® blood culture collection sets, announced that 3rd quarter revenues continued their record growth with the largest quarterly revenue in the company’s history. Kurin also reports that Q3 revenue grew 121% over revenue in the third quarter of 2019, before the pandemic began and a 43% increase over revenue in the third quarter of 2020, during the pandemic.

“Our continued growth during these challenging times is a testament to the quality of our professional team and the simplicity of Kurin,” said Bob Rogers, CEO of Kurin, Inc. “Hospitals are navigating through unprecedented times, but still must provide optimal care. Because Kurin does not require a change in practice, we are helping hospitals address the critical issue of blood culture contamination in a seamless manner.”

“Although any company would be pleased with this growth, it is particularly satisfying to note that each successive month of the quarter established new revenue highs, demonstrating continued acceleration of our business,” said Mr. Rogers. “We have been cash flow positive for months and this growth enables us to invest in increased capacity and some exciting future projects.”

Kurin’s revolutionary approach to the contaminated blood culture problem is an elegantly simple, intuitive design that requires no additional user steps. Kurin passively sidelines potential contaminants during blood culture collection. Kurin is a simply better and more sustainable approach over conventional mechanical diversion. Contaminated blood cultures are a significant problem, as roughly one-third of the positive results are wrong, exposing these patients to unnecessary antibiotics, extending hospital stays and impacting larger community health issues, such as antimicrobial resistance and the life-threatening C. diff. infection.

About Kurin, Inc.

Kurin Corporation, a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.

Kurin, Inc. announces UK clinical study results showing significant decrease in blood culture contaminations with the Kurin Lock™

Kurin Inc., the inventor and manufacturer of 510(k)-cleared Kurin® blood culture collection sets, announced today a new clinical study supporting the efficacy of their blood culture collection product. Authors from Guy’s and St. Thomas’ NHS Foundation Trust, a prestigious London-based hospital, presented their data at the recent Infection Prevention Society conference in Liverpool. They reported that blood culture contaminations were reduced 66% after implementing Kurin, and the authors noted both financial savings for their hospital, as well as a positive impact for their patients.

“We congratulate the clinicians at Guy’s and St. Thomas’ Hospital for publishing this data and providing optimal healthcare to their patients,” said Bob Rogers, CEO of Kurin. “It is rewarding to see the data in the UK so closely mirror the significant amount of data generated on Kurin’s efficacy in the US. Kurin is an elegant solution that allows hospitals to easily adopt this technology and hospitals have reported reductions in blood culture contaminations, improvement in patient care, financial benefits, and helping the community at large by preventing the use of inappropriate antibiotics.”

The patented Kurin Lock™ automatically sidelines approximately 0.15ml of initial blood and potential skin contaminants therein during blood culture collection. When skin microbes enter blood culture samples, false positive test results may misinform physicians and lead to unnecessary medical treatment, higher risk for patients, longer hospital stays, and significant costs for the hospital.

About Kurin, Inc.

Kurin Corporation, a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.

Kurin, Inc. Reports Record Sales Month

Kurin Inc., the inventor and manufacturer of the Kurin® blood culture collection sets, announced that July revenues represent their highest monthly total in their history. Kurin also reports that July exceeded 200% over the same month in 2019, before the pandemic began.

“We are living in unprecedented times with hospitals struggling in an unfamiliar world, so it is particularly rewarding to see the continued growth of our business,” said Bob Rogers, CEO of Kurin, Inc. “Demand for Kurin products is at an all-time high as we help hospitals manage their way through an uneven and unpredictable pandemic. We represent a source of clinical and financial improvement for hospitals, and the performance we have seen demonstrates that many hospitals see Kurin as a rare opportunity to improve on both levels.”

Kurin’s revolutionary approach to the contaminated blood culture problem is an elegantly simple, intuitive design that requires no additional user steps. The Kurin device passively sidelines potential contaminants during blood culture collection. Kurin is a simply better and more sustainable approach over conventional mechanical diversion. Contaminated blood cultures are a significant problem, as roughly one-third of the positive results are wrong, exposing these patients to unnecessary antibiotics, extending hospital stays and impacting larger community health issues, such as antimicrobial resistance and the life-threatening C. diff. infection.

About Kurin, Inc.

Kurin Corporation, a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.

Kurin, Inc. announces results on Kurin® efficacy from Oishei Children’s Hospital with zero blood culture contaminations

Kurin Inc., the inventor and manufacturer of 510(k)-cleared Kurin® blood culture collection sets, announced today that Oishei Children’s Hospital, a member of Kaleida Health, in Buffalo, NY, presented their findings on their use of Kurin at the recent Association for Professionals in Infection Control conference. This is the first study of Kurin, a passive low-volume blood culture collection device with flash technology in a pediatric population. The study was conducted over two periods and in combination, Kurin was used on 1,175 cultures without a single contamination.

“Congratulations to the authors from Oishei Children’s for publishing these important results and for providing this incredible level of care,” said Bob Rogers, Inventor and CEO of Kurin. “It is also of note that this is the first study that used our PIV products, which allow nurses the flexibility to draw a culture off a freshly placed IV, which is particularly important in this patient population.”

Kurin is the first device to allow for the passive sidelining of the initial flow of blood, providing clinicians a seamless path to compliance. Outcomes are driven by compliance and compliance is a function of how simple technology is integrated into practice, which can be particularly challenging in the busy Emergency Department and on these young patients. Kurin was also designed to use a remarkably low volume of blood, a significant improvement over other options, sidelining just 0.15 ml to achieve these clinical results, another critical requirement for pediatric patients.

“Early on, clinicians at Osihei Children’s gave us feedback on how to modify our product for their patient population, resulting in a small version of our PIV, and using a minimal amount of blood,” said Mr. Rogers. “Working with customers to optimize patient health is a meaningful part of why we are here. Our goal is to significantly improve patient outcomes while saving hospitals significant dollars and, given the special place kids have in all of our hearts, it is particularly heartwarming to see the impact that was made here.”

About Kurin, Inc.

Kurin Corporation, a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.

Kurin, Inc. Announces Removal of Magnolia Patent Infringement Lawsuit Trial Date

Kurin Inc., the inventor and manufacturer of Kurin® blood culture collection sets, announced that the U.S. District Court in Delaware has removed the trial date from the docket in the patent-infringement lawsuit brought against Kurin by Magnolia Medical.  The Court indicated that, if necessary, it will provide a trial date after it decides motions for summary judgment. This delay followed Magnolia Medical’s sudden replacement of their lead counsel, Fish & Richardson, with new counsel from the firm Davis Polk.

“As we said more than two years ago when they filed this suit, Magnolia’s case lacks merit and reveals a desperate company with an inferior product that struggles to compete with Kurin in the marketplace,” said Bob Rogers, CEO of Kurin and inventor of the Kurin Lock. “Since filing this lawsuit, they have dropped half of the asserted patents and have now switched law firms, which is never a sign of things going well. While it will likely take years of unnecessary litigation, we will see this through to a successful end.”

“Recently, we have seen Magnolia and its distribution partner offering a dramatic lowering of their price to $14, and we see this as further evidence that these are desperate times for them,” said Dave Lloyd, EVP of Sales and a Co-Founder of Kurin. “We do not know if this is special pricing to find new customers or whether all existing customers are offered this price, but it is another sign that they are struggling in the market.”

“From the beginning, Magnolia Medical has missed the mark with their complicated device,” said Mr. Rogers. “Whether through frivolous lawsuits, lower pricing, or other actions, they keep looking in the wrong place when the answer has always been more basic: clinical outcomes are tied to compliance and compliance is achieved by having a simple solution.”

Kurin’s revolutionary approach to the contaminated blood culture problem is elegantly simple, an intuitive design that requires no additional user steps. Kurin passively sidelines potential contaminants during blood culture collection – simply beyond conventional diversion.

About Kurin, Inc.

Kurin Corporation, a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.

Kurin, Inc. announces peer-reviewed publication on Kurin® efficacy from Central Texas Veterans Health Care System

Kurin Inc., the inventor and manufacturer of 510(k)-cleared Kurin® blood culture collection sets, announced today that the Central Texas VA Health Care System in Temple, TX, published their findings comparing results of two devices: Kurin and Steripath® (Magnolia Medical Technologies, Inc.) in the online edition of the Journal of Emergency Nursing. This is the first peer-reviewed publication comparing Kurin, a passive low-volume device with flash technology to Steripath, a mechanical diversion device using a much larger volume of blood. The study concludes that both products “drastically reduced [blood culture contamination rates], irrespective of the volume of initial diversion.” During the study, use of the Kurin collection sets resulted in a blood culture contamination rate of just 0.3%. 

“Congratulations to the authors from the Central Texas VA for publishing these important results,” said Bob Rogers, Inventor and CEO of Kurin. “The authors note that their results corroborate the peer-reviewed study from Hartford Hospital that showed Kurin reduced their blood culture contamination rate to below 0.5%, further strengthening the clinical foundation of Kurin.”

Kurin is the first device to allow for the passive sidelining of the initial flow of blood, providing clinicians a seamless path to compliance. Outcomes are driven by compliance and compliance is a function of how simple technology is integrated into practice, which can be particularly challenging in the busy Emergency Department. Kurin was also designed to use a remarkably low volume of blood, a significant improvement over other options, sidelining just 0.15 mls to achieve these clinical results.

“Although it is not stated in the clinical publication, after the study concluded, the facility allowed the nurses to decide which product to use and we are pleased they chose Kurin and in fact, have now been using Kurin for almost three years,” said Mr. Rogers. “Our goal is to significantly improve patient outcomes while saving hospitals significant dollars and, given the importance of the Department of Veterans Affairs to our country, there is no group we are more pleased to assist than our veterans and those providing their care.”

About Kurin, Inc.

Kurin Corporation, a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.

Kurin, Inc. honored by MD Tech Review in annual listing of top Infection Control solutions

The New Standard for Blood Culture Collection

Sepsis, is a life-threatening condition caused when the body’s response to an infection goes out of balance, which triggers changes that damage other organs. This deadly infection affects almost 1.7 million people a year in the U.S. and kills nearly 270,000 people. To date, blood cultures remain the gold standard for determining if a patient has sepsis. An early and accurate diagnosis of sepsis is essential to ensure better treatment for such patients.

However, contaminated blood cultures, also known as a false-positive blood culture result, lead to over one million misdiagnoses every year. Patients who are misidentified with sepsis might be treated for a bloodstream infection that they don’t have. This leads to more extended stays in hospitals and continued exposure to tests, drugs, and potentially to severe hospital-acquired conditions, all while the actual reason for admission remains unaddressed.

Helping address this pressing issue is Kurin, a certified Minority Business Enterprise (MBE) focused on the design, development, manufacture, marketing, and sale of products that can help healthcare providers reduce contaminated blood cultures. “Traditional blood culture collection methods provide skin microbes a direct line to the culture bottle. The Kurin blood culture collection set is a replacement for traditional collection sets, introducing technology to sideline skin contaminants while preserving the standard blood culture collection technique for clinicians,” says Bob Rogers, Founder, CEO and Chairman of the Board at Kurin.

A Challenge that Continues to Grow

To better illustrate the critical issue that Kurin strives to address, Rogers explains, “In the infection prevention (IP) world, there are several challenges revolving around sepsis, cultures, and the use of antibiotics.” Too often, these false-positive blood cultures are treated as infections, and some of them must be reported to the Centers for Disease Control and Prevention (CDC), even though the hospital eventually realizes they are not a true infection. Another major problem confronting those in IP is the presence of C. diff, a deadly infection, where antibiotic use is the largest contributor to the disease. As such, eliminating the use of antibiotics wherever possible is essential. There is also increasing concern over superbugs, bacteria that become resistant to antibiotics. Hospitals have antibiotic stewardship programs to reduce the use of antibiotics, and those who are placed on antibiotics because of an incorrect blood culture test would be a straightforward subset of patients to address.

For a long time, hospitals have used a three percent contamination rate as the standard performance benchmark, based on a 2005 Q Probe survey. However, currently, hospitals are using cutting-edge technologies to drive that contamination rate well below one percent. In fact, some recent researchers claim that it’s high time to use a one percent benchmark. For this, it is essential to understand what is often causing these contaminations. A major reason turns out to be the microbes on our skin.

Approximately 20 percent of microbes reside in the dermis layer, and when a needle penetrates the skin, some of these microbes are collected by the needle and can enter the blood culture bottle. Even scrubbing with an alcohol pad does not necessarily prevent sub-surface skin bacteria from getting into the sample. As a result, the analysis will show the presence of bacteria, which a hospital might conclude came from the patient’s bloodstream and, thus, diagnose them as having sepsis.

A straight forward method to prevent any possibility of contaminating the culture sample is to use empty vacuum tubes that are often called waste tubes or diversion tubes. The idea is simple—draw off a few milliliters (mls) of blood and throw the tube away. Keeping aside the fact that this process would require wasting a lot more blood than is needed, data shows that the contamination rates decline with the use of diversion technology.

In essence, it works!

However, the challenge here would be to convince people to actually comply with this practice. Most hospitals report their highest contamination rates are coming from the Emergency Department (ED) and the ED is an incredibly busy, high-stress place where immediate decisions and action can literally mean life and death. What might seem easy in one situation, like using an empty tube, has proven very difficult to maintain as a steady practice in a fast-paced ED. Once compliance to this practice drops, contamination rates will revert to their original level, which is what often happens with waste tubes. In addition to waste tubes, a device specifically intended for diversion has been on the market for years to address this problem. Obstacles to compliance of using this device include the large size of the device, which impacts both storage and disposal, the volume of blood used (1.5-2 mls), and the fact it takes a specific action by the person drawing the blood. This extra step, while not complicated, takes extra time and requires a newly-learned action, and just like with using a waste tube, these obstacles can impact compliance in a busy environment.

An Evolution Beyond Diversion

Being a leading figure in the medical devices space for the last 35 years, recognized for his pioneering contribution to the Luer-activated valve industry, Rogers knew well that to develop a solution to a problem, it is important to understand the drivers of the problem and ignore the confines of what others have said or done. Such wisdom can only come from a person who has done this before. For Rogers, his experience developing the Curos disinfecting cap—a disposable passive disinfection device, which was acquired by 3M Corporation in 2015—came in handy. In his words, “As important as developing a solution to the problem, in this case contaminated blood cultures, the invention has to take into account how the product will be used.”

Looking at the hectic environment where blood cultures are taken, the device has to fit, which means above all else, it must be simple. To truly impact clinical outcomes, the product must be easy to use and not just be something that works. And it is this evolution beyond diversion products that has helped Kurin be so successful.

When asked how he came up with the idea for this leap in technology, Rogers says, “When looking at a video of a blood culture test procedure, something didn’t happen that I was expecting to see. I thought I would see a flash of blood and when I realized why this did not occur, specifically that the blood culture set (also known as a butterfly set)is a sealed tube, blood flow/flash was prevented because air could not enter or exit. In my mind, this created an opportunity to simply address the skin/surface contaminant problem. In effect, I simply created a device with a hole in it to allow air to escape and designed the channels so the initial flash of blood flows into a side channel. This allowed for a technology that was small and it meant a nurse did not have to do anything differently.”

Kurin was designed to be extremely simple. It is integrated into a commonly used butterfly set, so those people drawing cultures are not learning anything new. Instead of a mechanical device where an action is taken to collect the blood, this device uses the patient’s blood pressure to fill a side channel with the initial blood and contaminants that are often in that skin plug. When a vacuum source, like a blood culture bottle, is attached, the blood from the vein then flows through an adjoining channel into the blood culture bottle. The Kurin Lock is incredibly small and only uses an extraordinarily small amount of blood, approximately 0.15 mls, to improve blood culture collection. Kurin has all of the advantages of the diversion products, but without the disadvantages that make compliance so challenging. Simple indeed!

The patented and FDA 510(k) cleared Kurin device transforms a regular blood culture collection set into a powerful yet simple way to put skin contaminants on the sideline. Each Kurin® collection set features industry-leading butterfly needles and is compatible with all major blood culture bottles. The integrated Kurin Lock® enables clinicians to automatically discard the initial flash of blood, which may contain skin microbes, with no change in collection practice.

A Robust Yet Simple Solution for Blood Culture Collection

Kurin has been helping hospitals around the country significantly reduce their contaminated blood cultures and generating Clinical Data to prove it. As an example, Hartford Hospital in CT published a peer-reviewed study where they reduced their contaminations from 1.7% to an amazing 0.44%, which is a 74% reduction.

Several other hospitals have presented similar data, meaning untold thousands of patients around the country have been spared the clinical problems of Contaminated blood cultures, and hospitals have saved tens of millions of dollars, just in the last year. The company has seen a significant increase in demand in the last few months—even during the pandemic.

For Rogers, the success of Kurin is yet another golden feather in the cap and he aims to up the ante in the next 12-18 months. “We continue to build a larger team and are expanding our manufacturing capabilities to support our growth. We believe that if we are not making a difference in saving lives and helping hospitals reduce costs, then we have no reason to be in business. We love what we do, and we are extremely driven to work on significant problems. Our goal with Kurin is simple—to help hospitals improve clinical outcomes and help their financial bottom line,” concludes Rogers.

Download the article as a PDF

About Kurin, Inc.

Kurin Corporation, a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.

Kurin, Inc. Named to Inc.’s Inaugural Best in Business List in the Prosperous and Thriving Category

Kurin, Inc. has been named to Inc.’s inaugural Best in Business list in the Prosperous and Thriving category. Inc. created the Best in Business Awards to honor companies that have gone above and beyond to make a positive difference.

The list, which can be found in the Winter issue of Inc. (on newsstands December 29, 2020), recognizes small- and medium-size privately held American businesses that have had a superlative impact on their communities, their industries, the environment, or society as a whole.

“We are honored to be recognized by Inc.,” said Bob Rogers, CEO of Kurin. “Our organization is focused on making a difference by helping hospitals improve their clinical outcomes and stem their financial losses from blood culture contaminations. It is rewarding to see our efforts recognized by others. The pandemic has created new challenges but strong demand for Kurin blood culture collection sets remains, and indeed has increased our rapid growth as hospitals understand, more than ever before, that accurate testing is critical to optimal patient health.”

Kurin’s revolutionary approach to the contaminated blood culture problem is an elegantly simple and intuitive design that requires no additional user steps. Kurin is a passive device that sidelines potential contaminants during blood culture collection—simply better than conventional diversion. Contaminated blood cultures are a significant problem, as roughly one-third of the positive results are wrong, exposing these patients to unnecessary antibiotics, extending hospital stays and impacting larger community health issues, such as antimicrobial resistance and the life-threatening C. diff. infection.

Scott Omelianuk, editor-in-chief of Inc., says, “It’s been an incredibly challenging year for companies. Across industries, businesses have had to make brutally tough decisions and face unprecedented uncertainty. That’s why we knew 2020 called for a new recognition program, something to complement our annual Inc. 5000 list of the fastest-growing private companies in the country. For Best in Business, companies have prioritized tackling today’s problems to lead us to a better future, even if they’ve struggled to stay in the black.” 

Instead of relying on quantitative criteria linked to sales or funding, Inc.’s editors reviewed the companies’ achievements over the past year and noted how they made a positive difference in the world. They then selected honorees in more than 30 different industries–health, software, retail, business services, and more–and in age- and revenue-based categories. The applicant pool was very competitive, with around 2,700 entries and an acceptance rate in the low single digits—a huge success for these honors in their inaugural year.

Honorees for gold, silver, bronze, and general excellence across industries and categories are featured online at inc.com/best-in-business.

About Kurin, Inc.

Kurin Corporation, a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.

Kurin, Inc. Receives Allowance from United States Patent and Trademark Office of Additional Claims to its Innovative Blood Culture Collection Device.

Kurin Inc., the inventor and manufacturer of 510(k)-cleared Kurin® blood culture collection sets, announced today that the United States Patent Office allowed its patent application and has issued U.S. Patent No. 10,827,964. The Kurin blood culture collection set is a replacement for traditional collection sets, enhanced with technology that sidelines skin contaminants while preserving the standard blood culture collection technique for clinicians.

“We continue to add to our intellectual property portfolio for our unique Kurin product line,” said Bob Rogers, Inventor and Chief Executive Officer. “We have been pleased with the rapid acceptance of Kurin in the marketplace, as hospitals continue to demonstrate interest in addressing the significant financial and clinical problems caused by contaminated blood cultures. This US patent further strengthens our position in the market. The simplicity of Kurin is critical to caregiver compliance and compliance is the key to improving clinical outcomes. With no need for manual manipulation, a Kurin set makes it effortless for clinicians to incorporate new technology into their routine collection process.”

Kurin’s revolutionary approach to the contaminated blood culture problem is elegantly simple, an intuitive design that requires no additional user steps. Kurin passively sidelines potential contaminants during blood culture collection—simply better than conventional diversion. Contaminated blood cultures are a significant problem, as roughly one-third of positive results are wrong, exposing these patients to unnecessary antibiotics, extending hospital stays, and impacting larger community health issues, such as antimicrobial resistance and the life-threatening C. diff. infection.

About Kurin, Inc.

Kurin Corporation, a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.

Kurin, Inc. Reports Record Revenues

>Kurin Inc., the inventor and manufacturer of the Kurin® blood culture collection sets, announced that third quarter revenues exceeded 150% over the same period in 2019. Kurin also reports that in the third quarter of 2020 sales have surpassed total revenues for 2019.

“Given the unprecedented times in which we find ourselves, we are pleasantly surprised to see a continuance of the strong demand that is fueling our rapid growth,” said Bob Rogers, CEO of Kurin, Inc. “Although the hospital world has changed, we’ve seen many hospitals implement Kurin during the pandemic, as they did not want to wait any longer to address their contaminated blood cultures. We have also seen an increase in the use of Kurin in many facilities underscoring the importance in the efficient use of resources and the fact that accuracy of tests has never been more important.”

Kurin’s revolutionary approach to the contaminated blood culture problem is elegantly simple, an intuitive design that requires no additional user steps. Kurin is a passive device that sidelines potential contaminants during blood culture collection—a method simply better than conventional diversion. Contaminated blood cultures are a significant problem, as roughly one-third of the positive results are wrong, exposing these patients to unnecessary antibiotics, extending hospital stays and impacting larger community health issues, such as antimicrobial resistance and the life-threatening C. diff. infection.

About Kurin, Inc.

Kurin Corporation, a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.